Drug intelligence / Profile preview

DS9051b

Development stage: Phase 1
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral

Overview

DS9051b is an orally administered small molecule anticancer drug under investigation for the treatment of advanced or metastatic adrenocortical carcinoma (ACC) and metastatic castration-resistant prostate cancer (mCRPC). It is being evaluated in a first-in-human, phase 1 clinical trial to assess its safety, tolerability, and preliminary efficacy in these patient populations. DS9051b is being developed by Daiichi Sankyo. The exact mechanism of action and target(s) have not been publicly disclosed, but it is designed as a targeted therapy for hard-to-treat neoplasms[1][2][3][4][5][6][11].

Beyond the preview

Go deeper on DS9051b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS9051b.

Explore the full profile